HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert(®) HIT) for the diagnosis of heparin-induced thrombocytopenia.

Abstract
A rapid lateral flow immunoassay (LFIA) (STic Expert(®) HIT), recently developed for the diagnosis of heparin-induced thrombocytopenia (HIT), was evaluated in a prospective multicentre cohort of 334 consecutive patients. The risk of HIT was estimated by the 4Ts score as low, intermediate and high in 28·7%, 61·7% and 9·6% of patients, respectively. Definite HIT was diagnosed in 40 patients (12·0%) with positive results on both enzyme-linked immunosorbent assay (Asserachrom(®) HPIA IgG) and serotonin release assay. The inter-reader reproducibility of results obtained was excellent (kappa ratio > 0·9). The negative predictive value of LFIA with plasma samples was 99·6% with a negative likelihood ratio (LR) of 0·03, and was comparable to those of the particle gel immunoassay (H/PF4-PaGIA(®) ) performed in 124 cases. Positive predictive value and positive LR were 44·4% and 5·87, respectively, and the results were similar for serum samples. The probability of HIT in intermediate risk patients decreased from 11·2% to 0·4% when the LFIA result was negative and increased to 42·5% when it was positive. In conclusion, the STic Expert(®) HIT combined with the 4Ts score is a reliable tool to rule out the diagnosis of HIT.
AuthorsDorothée Leroux, Nathalie Hezard, Aurélien Lebreton, Anne Bauters, Pierre Suchon, Emmanuel de Maistre, Christine Biron, Marie-Genevieve Huisse, Catherine Ternisien, Sophie Voisin, Yves Gruel, Claire Pouplard
JournalBritish journal of haematology (Br J Haematol) Vol. 166 Issue 5 Pg. 774-82 (Sep 2014) ISSN: 1365-2141 [Electronic] England
PMID24815503 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2014 John Wiley & Sons Ltd.
Chemical References
  • Heparin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Heparin (adverse effects)
  • Humans
  • Immunoassay (methods)
  • Male
  • Middle Aged
  • Nanoparticles (chemistry)
  • Prospective Studies
  • Thrombocytopenia (chemically induced, diagnosis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: